Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
COYA Coya Therapeutics
4.160+0.067+1.64%
Close
02/02 16:00 ET
High
4.350
Open
4.318
Turnover
96.60K
Low
3.685
Pre Close
4.093
Volume
24.34K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Coya Therapeutics, Inc. to Present Proof of Concept Clinical Data at Multiple Scientific Conferences Throughout 2023
COYA 301 (biologic monotherapy) clinical and biomarkers data in patients with Alzheimer's disease (AD) to be presented in 1H 2023 and 2H 2023 COYA 302 (biologics combination therapy) clinical and b
Coya Therapeutics, Inc.'s Quiet Period Set To End on February 7th (NASDAQ:COYA)
Coya Therapeutics' (NASDAQ:COYA – Get Rating) quiet period is set to end on Tuesday, February 7th. Coya Therapeutics had issued 3,050,000 shares in its IPO on December 29th. The total size of the off
Stocks That Hit 52-Week Lows On Friday
During Friday, 24 stocks hit new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Eastern Bankshares (NASDAQ:EBC).The smalles
Coya Data Supports Role of T-cells for Disease Modification in Alzheimer's
Coya Therapeutics, Inc. Highlights Publication Of An Article Titled 'Ex Vivo Expanded Human Regulatory T Cells Modify Neuroinflammation in a Preclinical Model of Alzheimer's Disease'
Coya Therapeutics, Inc. Highlights Publication Of An Article Titled 'Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer's Disease'
Coya Therapeutics Price Target Announced at $9.00/Share by Chardan Capital
Coya Therapeutics Price Target Announced at $9.00/Share by Chardan Capital
Coya Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/26/2023 88.28% Chardan Capital → $9 Initiates Coverage On → Buy What is the target price for Coya Thera
Chardan Capital Initiates Coverage On Coya Therapeutics With Buy Rating, Announces Price Target of $9
Chardan Capital analyst Keay Nakae initiates coverage on Coya Therapeutics with a Buy rating and announces Price Target of $9.
Coya Therapeutics Initiated With a Buy at Chardan
Coya Therapeutics, Inc. Announces Closing of $15.25 Million Initial Public Offering
Coya Therapeutics, Inc. ("Coya" or the "Company") (NASDAQ:COYA), a clinical-stage biotechnology company developing proprietary therapies to enhance the function of regulatory T cells ("Tregs"), today announced the
Company Overview
More
Coya Therapeutics, Inc. is a clinical-stage biotechnology company engaged in developing approaches utilizing Treg modifying therapeutics to target systemic and neuro inflammation. The company was founded by Howard Berman in 2020 and is headquartered in Houston, TX.
CEO： Dr. Howard Berman, PhD
Market： NASDAQ
Listing Date： 12/29/2022
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet